Pioneering the future of neuroscience derived from nature
Updates & Press Releases
Press Highlights
-
Healis Therapeutics Announces Partnership with CKD Bio
Healis announced it has entered into a supply agreement to develop CKDB-501 for neuropsychiatric indications
-
Healis selected to speak on opening day of 2024 Biotech Showcase in San Francisco
Healis team presenting on company's neurotherapeutics pipeline and clinical development.
-
Healis Therapeutics acquires ownership of key botulinum toxin patent
IP to accelerate the development of botulinum toxin as a candidate for treating major depressive disorder (MDD)